{"filing":{"accession_number":"0001213900-26-096447","cik":"0001885680","ticker":"RAJAF","company_name":"TFA Therapeutics, Inc.","form":"6-K","filing_date":"2026-09-02","report_date":"2026-09-02","primary_document":"ea0304187-6k_tfathera.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1885680/000121390026096447/ea0304187-6k_tfathera.htm"},"events":[{"id":31169,"run_id":28587,"accession_number":"0001213900-26-096447","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This exhibit is a private placement subscription agreement for the issuance of ordinary shares under Regulation S, targeting approximately US$10,000,000 (3,968,254 shares) with a maximum of up to 5,952,381 shares at US$2.52 per share. The agreement explicitly states the shares are unregistered under the Securities Act and offered solely in reliance on a Regulation S exemption to non-U.S. persons. This is a classic dilutive equity issuance that would materially affect shareholder ownership and capitalization.","company_name":"TFA Therapeutics, Inc.","ticker":"RAJAF","filing_date":"2026-09-02","form":"6-K","submitted_at":null,"items":[{"id":33985,"accession_number":"0001213900-26-096447","item_number":"EX-99.1","item_title":"ea030418701ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a private placement subscription agreement for the issuance of ordinary shares under Regulation S, targeting approximately US$10,000,000 (3,968,254 shares) with a maximum of up to 5,952,381 shares at US$2.52 per share. The agreement explicitly states the shares are unregistered under the Securities Act and offered solely in reliance on a Regulation S exemption to non-U.S. persons. This is a classic dilutive equity issuance that would materially affect shareholder ownership and capitalization.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-02T12:01:42.785802+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33985,"accession_number":"0001213900-26-096447","item_number":"EX-99.1","item_title":"ea030418701ex99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a private placement subscription agreement for the issuance of ordinary shares under Regulation S, targeting approximately US$10,000,000 (3,968,254 shares) with a maximum of up to 5,952,381 shares at US$2.52 per share. The agreement explicitly states the shares are unregistered under the Securities Act and offered solely in reliance on a Regulation S exemption to non-U.S. persons. This is a classic dilutive equity issuance that would materially affect shareholder ownership and capitalization.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-02T12:01:42.785802+00:00","company_name":"TFA Therapeutics, Inc.","ticker":"RAJAF","filing_date":"2026-09-02"}]}